FOGHORN THERAPEUTICS INC. - COMMON STOCK

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

16 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

09 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

05 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

26 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

07 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

05 Mar 2024 16:48:55 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference

28 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

08 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

08 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces CFO Departure

03 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

01 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs

24 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

13 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

04 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

05 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Chief Medical Officer Succession

08 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

04 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma

28 Jun 2023 07:00:00 By Nasdaq GlobeNewswire